One out of three patients with VTE does not receive the appropriate dose

More than 350 medical specialists attended the 12th Venous Thromboembolism (VTE) Forum that was held in Cuenca last week. Professionals of different VTE-related medical specialties presented new studies on deep vein thrombosis and pulmonary embolism based on data from the RIETE Registry.

Advances in anticoagulant treatment, as well as in cancer and thrombosis, are lines of clinical research that gained prominence in recent years in Spain and elsewhere.

Among the different studies presented, it is worth noting that one out of three patients with VTE does not receive the appropriate dose of anticoagulant treatment with the new direct-acting oral anticoagulants (rivaroxaban, dabigatran, apixaban and edoxaban). Neither the dose nor the administration regime are optimal, so these drugs are less effective and facilitate the recurrence of thrombosis and/or pulmonary embolism in the future.

In about 5% of patients, VTE is the first symptom of a cancer that is not yet evident, an occult neoplasm. Thanks to the RIETE Registry, it has been possible to identify patients in which this situation needs to be taken into account, as well as the types of cancer that these cases of thrombosis and pulmonary embolism flag.

A single dose of enoxaparin a day, instead of a dose every 12 hours, is safer for patients. The data show that patients bleed less frequently and die less frequently with the administration of a single dose, as allowed by law in Spain.

Taking acetylsalicylic acid (Aspirin) after anticoagulant treatment is finished helps to reduce recurrences of VTE. A daily dose for life prevents thrombi formation by favouring a more fluid state of the blood.

This edition of the VTE Forum also served as a setting for celebrating the 15th anniversary of the creation of RIETE Registry.